AffaMed Therapeutics Funding: $170M Raised, Series B (2021)
AffaMed Therapeutics is based in Shanghai, China. It has raised $170M in total funding. Latest round: Series B.
AffaMed Therapeutics funding overview
AffaMed Therapeutics is based in Shanghai, China. AffaMed Therapeutics has raised $170M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2021. The round record for AffaMed Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Lake Bleu Capital, Partners Investment, Superstring Capital, Orion Science Capital, Fountainhead Partners, CBC Group. 6 distinct backers are named across the disclosed rounds.
AffaMed Therapeutics at a glance
Total raised
$170M
Latest round
Series B
Latest round date
March 2021
Headquarters
Shanghai, China
Notable investors
Lake Bleu Capital, Partners Investment, Superstring Capital, Orion Science Capital, Fountainhead Partners, CBC Group
Frequently asked about AffaMed Therapeutics funding
How much has AffaMed Therapeutics raised?
AffaMed Therapeutics has raised $170M in total disclosed funding across the rounds on record.
Who has invested in AffaMed Therapeutics?
Lake Bleu Capital, Partners Investment, Superstring Capital, Orion Science Capital, Fountainhead Partners, CBC Group are named among the investors backing AffaMed Therapeutics.
What was the latest AffaMed Therapeutics funding round?
The most recent disclosed round is a Series B, announced in March 2021.
Where is AffaMed Therapeutics based?
AffaMed Therapeutics is based in Shanghai, China.
When did AffaMed Therapeutics last raise?
The last disclosed AffaMed Therapeutics round closed in March 2021 at Series B.
AffaMed Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
